参考文献

BAJEMA I M, HAGEN E C, HEER E D, et al, 2001. Colocalization of ANCA-antigens and fibrinoid necrosis in ANCA-associated vasculitis. Kidney International, 60 (5): 2025-2030.

BORCHERS A T, GERSHWIN M E, 2012. Giant cell arteritis: A a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmunity Reviews, 11 (6-7): 0-0A544-A554.

CORNEC D, GALL C L, FERVENZA F C, et al, 2016. ANCA-associated vasculitis ［mdash］clinical utility of using ANCA specificity to classify patients. Nature Reviews Rev Rheumatol, 12 (10): 570.

DESHPANDE V, ZEN Y, CHAN J K, et al, 2012. Consensus statement on the pathology of IgG4-related disease. Mod Pathol, 25 (9): 1181-1192.

EVANGÉLINE PILLEBOUT, THERVET E, HILL G, et al, 2002. Henoch-Schönlein Purpura in adults: Outcome and prognostic factors. J Am Soc Nephrol, 13 (5): 1271-1278.

JENNETTE J C, FALK R J, BACON P A, et al, 2013,. 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum, 65 (1): 1-11.

KARADAG O, JAYNE D, 2018. Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clin Exp Rheumatol, 36 (2): 135-142. Clinical &Experimental Rheumatology.

TAKAHASHI K T, OHARASEKITOSHIAKI O, YOKOUCHI Y, et al, 2007. Kawasaki disease arteritis and polyarteritis nodosa. Pathol Case Rev, 12 (5): 193-199.

MAHR A, AOUBA A, RICHEBÉ P, 2017. Epidemiology and natural history of giant cell arteritis.Eur J Int Med, 17 Suppl: 38 (10): 663-669.

MAKSIMOWICZ-MCKINNON K, CLARK T M, HOFFMAN G S, 2009. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine, 88 (4): 221-226.

MCCRINDLE B W, ROWLEY A H, NEWBURGER J W, et al, 2017. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation, 135 (17): e927-e999.

MENDES D, CORREIA M, BARBEDO M, et al, 2009. Behcet’s disease: a contemporary review.J Autoimmun, 32 (3-4): 178-188.

NEWBURGER J W, TAKAHASHI M, GERBER M A, et al, 2004. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young. Am Heart Assoc Pediatr, 114 (6): 1708-1733.

NORIS M, DAINA E, GAMBA S, et al, 1999. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation, 100 (1): 55-60.

SAMSON M, CORBERA-BELLALTA M, AUDIA S, et al, 2017. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev, 16 (8): 833-844.

STONE J H, TUCKWELL K, DIMONACO S, et al, 2017. Trial of tocilizumab in giant-cell arteritis. N Engl J Med, 377 (4): 317-328.

STONE J R, BRUNEVAL P, ANGELINI A, et al, 2015. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol, 24 (5): 267-278.

WATTS R A, ROBSON J, 2018. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol, 32 (1): 3-20.

WILDE B, VAN PAASSEN P, WITZKE O, et al, 2011. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney International, 79 (6): 599-612.